FDA is touting the approval of a naxolone auto-injector as part of a comprehensive opioid strategy, but its aggressive publicity surrounding the product risks being drowned out by concerns over its recent approval of Zohydro ER (single-entity hydrocodone).
FDA’s “Balanced Approach” To Opioids Extols Naloxone Auto-injector
Top government officials hold two briefings on FDA’s approval of a naloxone delivery device for reversal of opioid overdose as the agency faces continued criticism for approval of Zohydro XR.